Moderna Inc
$ 53.57
3.60%
27 Feb - close price
- Market Cap 20,931,600,000 USD
- Current Price $ 53.57
- High / Low $ 53.62 / 50.73
- Stock P/E N/A
- Book Value 21.95
- EPS -7.26
- Next Earning Report 2026-04-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.14 %
- ROE -0.29 %
- 52 Week High 55.20
- 52 Week Low 22.28
About
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$42.25
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-13 | 2025-11-06 | 2025-08-01 | 2025-04-30 | 2025-02-20 | 2024-11-07 | 2024-08-01 | 2024-05-02 | 2024-02-22 | 2023-11-02 | 2023-08-03 | 2023-05-04 |
| Reported EPS | -2.11 | -0.51 | -2.13 | -2.52 | -2.91 | 0.03 | -3.33 | -3.07 | 0.55 | -9.53 | -3.62 | 0.19 |
| Estimated EPS | -2.62 | -2.05 | -2.98 | -3.03 | -2.7599 | -1.9 | -3.38 | -3.58 | -0.97 | -1.93 | -4.04 | -1.77 |
| Surprise | 0.51 | 1.54 | 0.85 | 0.51 | -0.1501 | 1.93 | 0.05 | 0.51 | 1.52 | -7.6 | 0.42 | 1.96 |
| Surprise Percentage | 19.4656% | 75.122% | 28.5235% | 16.8317% | -5.4386% | 101.5789% | 1.4793% | 14.2458% | 156.701% | -393.7824% | 10.396% | 110.7345% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-30 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -2.11 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MRNA
2026-02-28 07:51:19
Analysts have adjusted their price targets and ratings for Vertex Pharmaceuticals (VRTX) following the company's fiscal Q4 and full-year 2025 earnings report. Canaccord and H.C. Wainwright raised their price targets, maintaining Hold and Buy ratings respectively, while Barclays slightly increased its price target with an Overweight rating. The company reported a 9% growth in full-year 2025 revenue, reaching $12.0 billion.
2026-02-27 21:40:23
Vertex Pharmaceuticals has diversified its portfolio beyond cystic fibrosis with the recent approvals of Casgevy, a gene-editing therapy for sickle cell disease and beta-thalassemia, and Journavx, a non-opioid acute pain medication. These new therapies target serious conditions, expanding Vertex's market and growth potential. While these launches provide new revenue streams, investors should monitor uptake, safety data, and competitive risks, as well as how the company balances investment in these new areas with its existing cystic fibrosis franchise and pipeline.
2026-02-27 20:38:43
The European Medicines Agency (EMA) has recommended market authorization for Moderna's combined mRNA COVID-19 and flu vaccine, mCombriax, for individuals aged 50 and older. This marks a significant milestone as it would be the first combined respiratory viral vaccine approved and the first mRNA flu shot globally. While the recommendation is a step towards approval, the European Commission still needs to adopt a decision for EU-wide marketing authorization.
2026-02-27 19:56:43
This article focuses on Moderna's performance in the market, highlighting its position among top gainers. It is part of the "Market Watch Rx" series from PharmExec News, which typically covers pharmaceutical industry trends and market movements.
2026-02-27 19:52:36
Structure Therapeutics reported positive Phase 2 results for its obesity drug aleniglipron, showing a placebo-adjusted weight loss of 15.3% at 36 weeks with no plateau observed. The company holds $1.4 billion in cash, expected to fund operations through the end of 2028, and plans to initiate a Phase 3 program for aleniglipron in the second half of 2026. Despite an increase in R&D and G&A expenses, the company posted a net income of $33.0 million for Q4 2025, largely due to license income and asset sales.
2026-02-27 18:51:06
European regulators have recommended authorization for Moderna's mCombriax, a combined flu and COVID-19 vaccine, for individuals aged 50 and older. This marks a significant step towards approval in the European Union, making it the world's first such combination vaccine. In contrast, the vaccine's approval in the United States remains uncertain due to strict FDA standards and additional hurdles, including initial reluctance from the Trump administration to review its application.
